- Tevogen Bio’s new facilities at CIC Philadelphia will expand the company’s research and development capabilities and will accelerate the advancement of its product pipeline.
- Tevogen’s scientists, technicians, and engineers will use the space to help simultaneously advance multiple preclinical studies and rapidly scale manufacturing capabilities.
Tevogen Bio, a clinical stage biotechnology company specializing in developing cell and gene therapies in oncology, neurology, and virology, today announced new laboratory space has been secured at CIC Philadelphia to facilitate the company’s rapid expansion of its R&D, process development, and analytical capabilities to allow for further advancement of its next generation precision T cell technology programs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005590/en/
Tevogen Bio’s new laboratory space is located at CIC Philadelphia, University City Science Center (Photo: Business Wire)
These highly equipped laboratories, which the company plans to begin utilizing in June, will serve as a location for Tevogen’s ongoing preclinical research, process development, and analytical teams. Tevogen’s scientists, technicians, and engineers will use the space to help simultaneously advance multiple projects and rapidly scale manufacturing capabilities. The laboratory space will also accommodate the company’s ongoing recruitment of highly specialized R&D personnel.
“As a company, we are dedicated to sustained medical innovation and a key component of that is expanding our research and development and key operational processes. These new laboratories will allow us to reach that goal,” said Stephen Chen, Tevogen’s Chief Technical Officer. “We are excited to work with CIC Philadelphia which offers state of the art laboratory space where our scientists and innovators will be able to execute on multiple preclinical research projects simultaneously.”
“Tevogen’s rapid growth from concept to a fully operational biotech in less than 23 months is the culmination of ambitious goals and flawless execution of well-orchestrated strategies by its highly motivated and skilled team of experts,” said Ryan Saadi, Tevogen’s Chairman and Chief Executive Officer. “The addition of the new facilities at the CIC along with Tevogen’s forthcoming Philadelphia R&D center will provide us the resources to further catalyze our product pipeline expansion activities,” Saadi added.
About Tevogen’s Next Generation Precision T Cell Platform
Tevogen’s next generation precision T cell platform is designed to provide increased specificity to eliminate malignant and viral infected cells, while allowing healthy cells to remain intact. Multiple targets are selected in advance with the goal of overcoming mutational capacity of cancer cells and viruses.
Tevogen believes its technology has the potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen’s goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.
The company’s lead product, TVGN-489, is currently in clinical trials for high-risk COVID-19 patients at Jefferson University Hospitals in Philadelphia. TVGN-489 is a highly purified, SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte (CTL) product, which is designed to detect targets spread across the entire viral genome.
Tevogen recently announced it has completed dosing of the second cohort of patients in the proof of concept clinical trial of TVGN-489, marking the midway point of the trial’s planned four dosing levels. Trial details and recruitment information are available at Clinical Trials - Tevogen.
About Tevogen Bio
Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.
Forward Looking Statements
This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc (the “Company”) and its business. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the Company’s control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “believe,” “potential,” “possible,” or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between the Company’s expectations and actual results, including, among others: the Company’s limited operating history; uncertainties inherent in the execution, cost and completion of preclinical studies and clinical trials; risks related to regulatory review and approval and commercial development; risks associated with intellectual property protection; and risks related to matters that could affect the Company’s future financial results, including the commercial potential, sales, and pricing of the Company’s products. Except as required by law, the Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions herefrom.
Corporate Communications Lead